The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1697
March 4, 2024
View Complete Issue         Table of Contents 2019 
Tenapanor (Xphozah) for Hyperphosphatemia in Chronic Kidney Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Tenapanor (Xphozah) for Hyperphosphatemia in Chronic Kidney Disease
March 4, 2024 (Issue: 1697)
The FDA has approved the sodium/hydrogen exchanger 3 (NHE3) inhibitor tenapanor (Xphozah – Ardelyx) to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy when phosphate binders are ineffective...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Tenapanor (Xphozah) for Hyperphosphatemia in Chronic Kidney Disease
Article code: 1697b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.